Sign In
Buy SYRE
$98.33
-3.17 (-3.12%)
At Close: Jul 31, 2026
Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
04:05pm, Monday, 08'th Sep 2025
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company advancing best-in-class antibody e
Spyre Therapeutics Announces Grants of Inducement Awards
04:05pm, Friday, 05'th Sep 2025
WALTHAM, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody e
Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:02pm, Tuesday, 05'th Aug 2025
Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ("PK") profiles supporting quarterly or biannual do
Spyre Therapeutics Announces Grants of Inducement Awards
04:41pm, Friday, 01'st Aug 2025
WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody en
Spyre Therapeutics Announces Grants of Inducement Awards
04:05pm, Thursday, 03'rd Jul 2025
WALTHAM, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody en
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward
02:58pm, Wednesday, 18'th Jun 2025
Spyre Therapeutics, Inc.'s SPY002 and SPY072 drug candidates showed strong safety and TL1A inhibition in a phase 1 study, supporting advancement to phase 2 clinical development. SPY002 targets ulcerat
SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more th
WALTHAM, Mass. , June 16, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rati
Spyre Therapeutics Announces Grants of Inducement Awards
04:05pm, Friday, 06'th Jun 2025
WALTHAM, Mass. , June 6, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, d
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know
10:55am, Friday, 30'th May 2025
The mean of analysts' price targets for Spyre Therapeutics (SYRE) points to a 244.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
08:30am, Wednesday, 28'th May 2025
WALTHAM, Mass. , May 28, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, d
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
11:00am, Tuesday, 13'th May 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 258.3% in Spyre Therapeutics (SYRE). While the effectiveness of this highly sought-after metric is questionable
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Thursday, 08'th May 2025
On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts in 2026 & 2027 Reported extended f
SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD) SPY001 pharmacokinetic (PK) data up to eight months continues to support a po
Spyre Therapeutics Announces Grants of Inducement Awards
04:05pm, Friday, 02'nd May 2025
WALTHAM, Mass. , May 2, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, do
